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Abstract
Background: After primary treatment for breast cancer, patients are recommended to use hospital follow-up care
routinely. Long-term data on the utilization of this follow-up care are relatively rare.
Methods: Information regarding the utilization of routine hospital follow-up care was retrieved from hospital
documents of 662 patients treated for breast cancer. Utilization of hospital follow-up care was defined as the use
of follow-up care according to the guidelines in that period of time. Determinants of hospital follow up care were
evaluated with multivariate analysis by generalized estimating equations (GEE).
Results: The median follow-up time was 9.0 (0.3-18.1) years. At fifth and tenth year after diagnosis, 16.1% and
33.5% of the patients had less follow-up visits than recommended in the national guideline, and 33.1% and 40.4%
had less frequent mammography than recommended. Less frequent mammography was found in older patients
(age > 70; OR: 2.10; 95%CI: 1.62-2.74), patients with comorbidity (OR: 1.26; 95%CI: 1.05-1.52) and patients using
hormonal therapy (OR: 1.51; 95%CI: 1.01-2.25).
Conclusions: Most patients with a history of breast cancer use hospital follow-up care according to the guidelines.
In older patients, patients with comorbidity and patients receiving hormonal therapy yearly mammography is
performed much less than recommended.
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Background
Breast cancer is the commonest incident form of malig-
nancy among women in Europe[1]. Advances in the
early diagnosis and treatment of breast cancer increase
the number of breast cancer survivors[2]. Nowadays, it
is estimated that more than 80% of the patients with a
history of breast cancer will survive longer than 5 years
and more than 60% of these patients will survive longer
than 10 years[3,4]. After primary treatment, these
patients are offered routine hospital follow-up. One of
the main aims is to early detect loco-regional recur-
rences and second primary tumours. Approximately
40% of the isolated locoregional recurrences are diag-
nosed during routine visits and routine tests in asympto-
matic patients treated for early-stage invasive breast
cancer [5]. In a recently published meta-analysis it was
shown that the detection of isolated loco-regional or
contra-lateral breast cancer recurrences in patients with-
out symptoms has beneficial impact on survival of
breast cancer patients when compared to late sympto-
matic detection, indicating that regular hospital follow-
up might be beneficial for some patients [6]. Although
recommendations vary to some extent with regards to
timing, routine hospital follow-up visits include history
taking, physical examination and mammography are
part of the schedule. Health care utilization after pri-
mary treatment for women with a history of breast can-
cer represents a major public health issue with
increasing importance [7,8].
Routine hospital follow-up care is a major portion of
health care use of breast cancer survivors [8]. There is a
limited number of studies examining the health care use
of long-term follow up care of breast cancer survivors
including hospital visits (history taking and clinical
examination) and mammography[9,10]. Data on utiliza-
tion of long-term follow-up care beyond five years of
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factors associated with the utilization of long-term fol-
low-up care [7,11]. The aim of the current study was to
assess the use of long-term routine hospital follow-up
care, to describe the reasons of stopping this follow-up
care, and to assess the determinants of the use of this
routine hospital follow-up care. For that we derived
information from hospital documents of 662 patients
treated for breast cancer.
Methods
Settings and subjects
The regional cancer registry of the Comprehensive Can-
cer Centre North-Netherlands (CCCN, merged into the
Comprehensive Cancer Centre Northeast-Netherlands
in 2009) was used to select the patients who were diag-
nosed with breast cancer from January 1989 to January
2003. This cancer registry contains data on diagnosis,
stage, and treatment actively abstracted from the
patient’s medical records in all hospitals within the
CCCN catchment area using the registration and coding
manual of the Dutch Association of Comprehensive
Cancer Centres. Passive follow-up of vital status through
municipal population registries is conducted and the
vital status of patients is updated annually.
Of these 5,589 women a total of 139 patients devel-
oped contra lateral breast cancer (CBC) after six months
since the first tumour and those contra lateral breast
cancers were registered in the database. Because follow-
up data was not available in the cancer registry, and we
were not able to retrieve the follow-up data from all
5,495 patients from the hospital files. We decided to
over-sample the women with contralateral breast cancer
and sampled a subset of women without contralateral
breast cancer. This cohort is representative of breast
cancer survivors at a greater risk of secondary breast
cancer supposed to have a better utilization of follow-up
procedures. For each woman with CBC, four to five
patients without evidence of CBC - matched with hospi-
tal of diagnosis, age at first primary tumour, and dura-
tion of follow-up - were selected randomly in this
cohort. Based on this a cohort of 736 patients was con-
structed including all women with a CBC. Medical
documents were unavailable for 67 (9.1%) patients, and
for seven (1.0%) patients there was no information avail-
able on the follow-up. Finally, there were 662 (89.9%)
patients in our study with information concerning at
least one year follow-up (See Figure 1).
Data abstraction
For all patients in our study, the follow-up information
was retrieved actively from hospital documents, includ-
ing date and content of visits, date of mammography. In
addition, data on family history and comorbidity were
retrieved for the patients in our study, as these data
were not included in the cancer registry. Comorbidity
was assessed with the use of the slightly modified Charl-
son comorbidity index [12,13]. Per visit, it was retrieved
whether patients came to the hospital with or without
symptoms. In addition information on the following
events was retrieved: the incidence of any loco-regional
recurrences, contra-lateral breast cancers, distant metas-
tasis or death. The time of ending hospital follow-up
and the reason was retrieved as well. The information
on whether the patient went to the Dutch National
Breast Cancer Screening Program was derived from
linkage between the CCCN and the Dutch National
Breast Cancer Screening Program.
Follow-up guidelines in the study period
After surgical treatment for breast cancer, follow-up was
offered four times a year in the first two years. After
two years it was offered two times a year and after five
years it was offered once a year. Follow-up included his-
tory and physical examination. Mammography was
offered once in two years (guidelines published in 1987).
In 1994 the preferred frequency of mammography was
changed from once in two years to yearly. The duration
for follow-up was not specified. In the Northern part of
the Netherlands, in 1999 follow-up was stratified for age
groups. If the patient was under the age of 70 at the
start of surgical treatment, hospital follow-up was
offered for a period of 10 years, and after that period
patients were referred back to their General Practitioner.
If the patient was 70 or older at the start of surgical
treatment, hospital follow-up was offered for a period of
5 years, and after that period patients were referred
back to their GP. In 2003 the age cut-off was changed
67 patients without available medical 
documents (excluded)
139 patients with 
CBC
5495 patients with a
ipsilateral breast cancer
5589 patients with a 
new breast cancer
94 patients with synchronous CBC 
(excluded) 
597 patients were 
matched
669 patients with available
medical documents
662 patients were 
included
7 patients without available follow-up
information (excluded) 
Figure 1 Graphical illustration of the sampling of study cohort
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Page 2 of 7from 70 to 65 and the option to refer patients to the
Dutch National Breast Cancer Screening Program was
added after the ending of the hospital follow-up. That
time breast cancer screening in the Dutch National
Breast Cancer Screening Program was offered to all
women from 50 till 75 years of age.
Definitions
For each patient, the time for routine hospital follow-up
was assessed. The routine hospital follow-up time was
considered to be ended if the patient was diagnosed
with a loco-regional recurrence, a contra-lateral recur-
rence, a distant metastasis or death. In addition, the
routine hospital follow-up time was considered to be
ended if there was a note in the files about ending the
follow-up which was not followed by any other follow-
up visit. When there is no record of ending the routine
hospital follow-up, the retrieval date was considered as
the last date of follow-up.
If a visit or a diagnostic mammography was related to
a patient that presented with symptoms, the related visit
and the related diagnostic mammogram were not con-
sidered as being part of routine hospital follow-up and
these visits were excluded from the analysis.
The utilization of hospital follow-up for every follow-
up person-year was evaluated after 1994 when the fre-
quency of follow-up was recommended to be given once
a year. This hospital follow-up was evaluated according
to the guidelines of follow-up of patient with a breast
cancer. Underuse of hospital follow-up was defined as
there was no hospital follow-up in patients who sup-
posed to have hospital follow-up during that period
according to the guidelines. The underuse of mammo-
graphy was defined as having no mammogram in a per-
iod of at least 14 months in women who were followed-
up in hospital. Women whose time between two mam-
mograms was less than 10 months were first identified
and then evaluated whether the second mammogram
was appropriate according to the guidelines, if not, it
w o u l db ec o n s i d e r e da sa no v e r u s eo fa n n u a l l y
mammography.
Statistical analysis
Determinants potentially related to the underuse of hos-
pital follow-up care, mammography were evaluated in a
multivariate model by generalized estimating equations
(GEE) which accounted for the dependent outcomes
within breast cancer survivors. Odds ratios (OR) were
calculated to reflect the potential associations between
determinants and outcomes. Outcomes considered were
whether patients underused hospital visits or yearly
mammography after primary treatment (yes or no).
Determinant potentially related were age at primary
diagnosis, year at diagnosis, year after primary
treatment, whether the first tumour was detected during
national breast cancer screening program, family history,
comorbidity, characteristics of first tumour and treat-
ment for first tumour. The periods of each constant
guideline were taken into accounted as covariate. Only
results from multivariate analyses are presented.
Results
Patients’ characteristics
Of the 662 women included in this study, 197 (29.8%)
patients were younger than 50 years of age at diagnosis
of the first tumour and the median age was 57.7 (26-
93). Family history of breast cancer was present in 150
(22.7%) patients and comorbidity was present in 276
(41.7%) patients. 423 (63.9%) patients had mastectomy
and 214(32.3%) had had breast conserving therapy for
their first tumour. 20.1% of the patients received che-
motherapy, and 138(20.8%) of the patients received hor-
monal therapy. The median follow-up time was 9.0
years (0.3-18.1) (See Table 1).
Ending of hospital follow-up
Of the 662 women, routine hospital follow-up was
documented to be ended for 247(37.3%) among which
90 (36.4%) patients the time of stopping their hospital
follow-up was earlier than it would have been based on
the guidelines. Out of these 90 patients, 38 (42.2%)
patients followed the doctor’s advice to stop being hos-
pital follow-up. 18 (20.0%) patients themselves decided
to stop hospital follow-up, 9 (10.0%) patients stopped
routine hospital follow-up because of comorbidity and
25 (27.8%) patients were transferred to the National
Breast Cancer Screening Program sooner than was
recommended by guidelines. 178 (72.1%) out of 247
patients were younger than 75 years of age at the time
of ending their routine hospital follow-up. Of these, 156
(63.2%) patients were between 50 and 75 years and, 48
(30.7%) patients were transferred to the National Breast
Cancer Screening Program. For 90 (36.4%) patients the
time of stopping their hospital follow-up was earlier
than it would have been based on the guidelines.
Utilization of hospital follow-up visits
The long-term routine hospital follow-up visits
decreased over time gradually. 2.4%, 16.1% and 33.5%
patients had less follow-up visits than recommended in
the national guideline at the first, fifth and tenth year
after treatment (see Table 2). The total number of regis-
tered contacts was 10,553. Patients had an average of
five visits in the first year, three times in the second
year, twice in the third to fifth year and once in the
years after. During their hospital follow-up, 109 (16.5%)
patients were found both to underuse and to overuse
hospital follow-up visits, 221 (33.4%) patients were
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patients were found to overuse hospital follow-up visits
and 233 (35.2%) patients were compliant with the
recommended frequency of hospital follow-up visits.
In the multivariate model, as compared to patients
aged 50-69 years, women who had breast cancer diag-
nosed after 70 years of age were less likely to underuse
hospital follow up (OR: 0.64, 95%-CI: 0.44-0.89).
Women who receive radiotherapy for the first tumour
were less likely to underuse the hospital follow-up (OR:
0.53, 95%-CI: 0.29-0.95). Compared to the first five
years after primary treatment, women were more likely
to underuse the hospital follow up in the sixth to the
tenth year from the primary treatment of first tumour
(OR: 2.86, 95%-CI: 2.26-3.62).
Utilization of mammography
Only 44.1% patients had a mammogram with 14 months
after completion of primary treatment. 33.1% and 40.4%
of the patients had less mammogram in the fifth and
tenth year after primary treatment, respectively (see
Table 2). During their hospital follow-up, 112 (17.0%)
patients were found both to underuse and to overuse
mammography, 506 (76.7%) patients were found to
underuse mammography, 12 (1.8) patients were found
to overuse mammography and 30 (4.5%) patients were
compliant with the recommended frequency of
mammography.
In the multivariate model evaluating the potential fac-
tors associated with the underuse of mammography,
older age (age > 70; OR: 2.10; 95%CI: 1.62-2.74),
patients with co-morbidities (OR: 1.26; 95%CI: 1.05-
1.52) and hormonal therapy (OR: 1.51; 95%CI: 1.01-
2.25). Patient with their first tumour diagnosed after
1994 (OR: 0.74; 95%CI: 0.60-0.92), patients with positive
lymph node at the first tumour (OR: 0.65; 95%CI: 0.42-
0.98) and patients who received radiotherapy (OR: 0.73;
95%CI: 0.55-0.98) were less likely to underuse yearly
mammography. After five years of follow-up, patients
were more likely to underuse yearly mammography
according to the guidelines (for 6-10 year was OR: 1.74;
95%CI: 1.48-2.06 and OR for 10+ year was 8.21, 95%-CI:
6.05-11.14, see Table 3).
Discussion
This study evaluated utilization of hospital follow-up in
a cohort of 662 patients with a median follow-up time
of 9.0 years (range: 0.1-18.2). At fifth and tenth year
after diagnosis, 16.1% and 33.5% of the patients were
under using hospital follow-up care, respectively, where
of the patients in hospital follow-up, 33.1% and 40.4% of
the patients were under using mammography, respec-
tively. Underuse of yearly mammography was found in
older patients (age > 70; OR: 2.10; 95%CI: 1.62-2.74),
patients with comorbidity (OR: 1.26; 95%CI: 1.05-1.52)
and patients with hormonal therapy (OR: 1.51; 95%CI:
1.01-2.25).
Routine hospital follow-up care was ended for 37.3%
(n = 247) recurrence-free patients. For one-third of
these patients (n = 90; 36.4%) the time of stopping their
hospital follow-up was earlier than it should have been
based on the guidelines. According to the guidelines,
women with a history of breast cancer should be advised
to be followed-up until age of 75 either in hospital or
being transferred to the National Breast Cancer Screen-
ing Program. Only one-third of the patients who were
Table 1 Characteristics of patients and their first breast
cancer n (%)
Characteristics N %
Age at diagnosis [median(range) yrs] 57.7 26-93
Age group at diagnosis
<50 197 29.8
50-59 172 26.0
60-69 163 24.6
70+ 130 19.6
Year of diagnosis
1989-1993 313 47.3
1994-2002 349 52.7
Detecting first tumour by Screening programme
No 335 72.0
Yes 130 28.0
No applicable 197
Co morbidity
No 386 58.3
Yes 276 41.7
Pathologic T stage
pTis/T1 376 57.7
pT2-3 276 42.3
Unknown 10
Pathologic N stage
N0 435 62.2
N1-3 212 37.8
Unknown 10
Surgery
BCT 214 33.6
Mastectomy 423 66.4
Unknown 25
Radiation therapy
Yes 284 42.9
No 378 57.1
Chemotherapy
Yes 98 20.8
No 564 79.2
Hormonal therapy
Yes 138 79.2
No 524 20.8
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low-up were indeed transferred to the National Breast
Cancer Screening Program. Patients between the age of
50 and 75, ending their routine hospital follow-up pro-
gram should be well actively referred to the National
Breast Cancer Screening Program. Recently this was
added to the Dutch national guideline for breast cancer
screening [http://www.oncoline.nl/index.php?pagina=/
richtlijn/item/pagina.php&richtlijn_id=593].
Patients who received radiation therapy for their pri-
mary tumours and women with positive lymph node at
the first tumour were less likely to underuse the routine
hospital follow-up. This might be a reflection of more
concern about the risk of breast cancer recurrences and
the more consequent recall policy of the radiation
oncologist.
Compared to first five years after primary treatment,
women were more likely underuse the hospital follow
up in the sixth to the tenth year from the primary treat-
ment of first tumour (OR: 2.86, 95%-CI: 2.26-3.62). This
finding is consistent with another research and the
decreasing concern about the risk of breast cancer over
time may be a possible explanation for declining routine
hospital follow-up visits [14].
In this study, the utilization of mammography was
evaluated in women who were followed up in hospital.
For patients who stopped their hospital follow-up, the
utilization of mammography was not evaluated. Mam-
mography is the only recommended imaging test for the
routine follow-up of womenw i t hah i s t o r yo fb r e a s t
cancer and is recommended by most guidelines [15].
Underutilization of mammography was still found in 30-
40% patients during the routine hospital follow-up
phase in this study. Several studies reported that elderly
patients are less likely to receive routine mammography
[14,16] which is also the case in this study, patients over
70 had a lower chance to receive yearly mammography.
An explanation might be that among elderly, there is a
decreasing concern about the risk of breast cancer
recurrences [16]. Lower use among the elderly could be
related to competing medical needs and/or perceived
diminishing benefit from regular mammography with
advancing age also. Patients who had comorbidity and
Table 2 Utilization of breast cancer follow-up care in breast cancer survivors
Time after treatment (years) Disease free Patients* Patients used hospital follow-up visit Patients used yearly mammography
nn % n %
1 662 639 96.5 282 44.1
2 634 587 92.6 412 70.2
3 613 548 89.4 368 67.2
4 590 503 85.3 331 65.8
5 570 478 83.9 320 66.9
6 538 447 83.1 277 62.0
7 516 400 77.5 246 61.5
8 470 340 72.3 208 61.2
9 425 300 70.6 194 57.1
10 361 240 66.5 143 59.6
* Patients who have a loco-regional recurrence or contra-lateral breast cancer were excluded. Patients who have distant metastasis were excluded.
Table 3 Predictive factor of underuse of follow-up care in
breast cancer survivors (multivariate results)
Variable OR 95% CI
Underuse of hospital follow-up
Age at diagnosis <50 1.42 0.95-2.11
50-69 1
70- 0.64 0.42-0.96
Year at diagnosis 1989-1993 1
1994-2002 0.63 0.44-0.89
Year after primary treatment 1-5 1
6-10 2.86 2.26-3.62
10+ - -
Radiation therapy No 1
Yes 0.53 0.29-0.95
Underuse of yearly of mammography
Age at diagnosis <50 1.29 1.00-1.67
50-69 1
70- 2.10 1.62-2.74
Year at diagnosis 1989-1993 1
1994-2002 0.74 0.60-0.92
Year after primary treatment 1-5 1
6-10 1.74 1.48-2.06
10+ 8.21 6.05-11.14
Co morbidity No 1
Yes 1.26 1.05-1.52
pN stage N0 1
N1/N2/N3 0.65 0.42-0.98
Radiation therapy No 1
Yes 0.73 0.55-0.98
Hormonal therapy No 1
Yes 1.51 1.01-2.25
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mograms than advised. These findings may reflect
potentially appropriate decis i o n sb yp a t i e n t so rt h e i r
physicians for less intensive care as a result of compet-
ing comorbid illness causing that follow-up mammogra-
phy became a lower priority in these patients[14,16,17].
The finding that the patients who received hormonal
therapy had less frequent mammography than advised
might be a reflection of the awareness of the decreasing
efficiency of mammography in follow-up after recalcu-
lating the incidence of local recurrences which is
reduced by hormonal therapy. The patients with a first
tumour diagnosed after 1994 were more likely to have
yearly mammography probably due to the increasing
awareness of the benefit of mammography and the pub-
lications of guideline on follow-up of breast cancer
which addressed the importance of mammography
[18-20].
As well as the use of routine hospital follow-up, the
use of yearly mammography decreased gradually over
years. It may be an effective and safe choice to transfer
women with a history of breast cancer to their general
practitioner to keep the continuity of care at an appro-
priate time[21]. This may reflect tailored follow-up sche-
dules, where the estimated risk of recurrence influences
the choice to adhere to the follow-up schedule as in the
national guidelines or to decrease the number of follow-
up visits and examinations. Because the recurrence rate
in the study population cannot be assessed reliable from
the present data, this hypothesis cannot be tested.
Caution is needed when generalizing study results and
conclusions to other population and settings. Our study
cohort consists of patients with metachronous contra-lat-
eral breast cancers and random group stratified on hospi-
tal of diagnosis, age and duration of follow-up. This
cohort is representative of breast cancer survivors at a
greater risk of secondary breast cancer who are expected
to be under close surveillance. The other limitation of
present study is we only reviewed the utilization of hospi-
tal follow-up. It is still unclear whether patients who stop
their hospital follow-up were followed up in the National
Breast Screening Program or in general practice routinely
or not. From other research it became clear that patients
who continued to see cancer specialists after their initial
cancer treatment were more likely than other patients to
undergo routine follow-up mammography [22,23]. The
utilization of follow-up care elsewhere such as the
National Breast Screening Program or in general practice
for long term survivors deserves further research. The
consequence of underuse of hospital follow-up is not
clear due to the lack of conclusive evidence in the litera-
ture about the benefit of regular hospital follow-up visits,
either in terms of early detection of recurrences or in
relation to psychological well-being.
Conclusions
Most patients with a history of breast cancer use hospi-
tal follow-up care according to the guidelines. In older
patients, patients with comorbidity and patients receiv-
ing hormonal therapy we should be careful to ensure
the use of yearly mammography.
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